Serious Adverse Events Associated with Off-Label Use of Azithromycin or Fentanyl in Children in Intensive Care Units: A Retrospective Chart Review
- 36 Downloads
Half of prescription drugs commonly given to children lack product labeling on pediatric safety, efficacy, and dosing. Two drugs most widely used off-label in pediatrics are azithromycin and fentanyl. We sought to determine the risk of serious adverse events (SAEs) when oral azithromycin or intravenous/intramuscular fentanyl are used off-label compared to on-label in pediatric intensive care units (ICUs).
Six pediatric hospitals participated in a retrospective chart review of patients administered oral azithromycin (n = 241) or intravenous/intramuscular fentanyl (n = 367) between January 5, 2013 and December 26, 2014. Outcomes were SAEs by drug and labeling status: off-label compared to on-label by Food and Drug Administration (FDA)-approved age and/or indication. Statistical analysis was performed using logistic regression to estimate odds ratios (ORs) and Cox regression to estimate hazard ratios (HRs).
Twenty-one (9%) children receiving azithromycin experienced SAEs. Off-label use of azithromycin was not associated with a higher risk of SAE (OR 0.87, 95% CI 0.27–2.71, p = 0.81). Ninety-five (26%) children receiving fentanyl experienced SAEs. Fentanyl off-label use by both age and indication was not associated with a higher risk of overall SAEs compared to on-label use (OR 1.99, 95% CI 0.94–4.19, p = 0.07). However, the risk of the SAE respiratory depression was significantly greater when fentanyl was used off-label by both age and indication (OR 5.05, 95% CI 1.08–23.56, p = 0.044). Results based on HRs were similar.
Azithromycin off-label use in pediatric ICUs does not appear to be associated with an increased risk of SAEs. Off-label use of fentanyl appears to be more frequently associated with respiratory depression when used off-label by both age and indication in pediatric ICUs. Prospective studies should be undertaken to assess the safety and efficacy of fentanyl in the pediatric population so that data can be added to the FDA labeling.
We thank Drs. Mark Levenson and Elande Baro for their guidance with the statistical analysis on this project. This work was supported by UL1 TR000445 to Vanderbilt University Medical Center, T32 GM007569 (KAO) and Burroughs Wellcome Fund IRSA 1015006 (SLV).
Compliance with Ethical Standards
Kazeem A. Oshikoya, Gerold T. Wharton, Debbie Avant, Norman E. Fenn, Allison Lardieri, Edwin Doe, Beena G. Sood, Carol Taketomo, Phuong Lieu, Lilly Yen, and Ann W. McMahon have no conflicts of interest. Sara L. Van Driest has been an invited speaker to Merck and received an honorarium. No additional funding was provided for this study. The opinions expressed in this article are those of the authors and should not be interpreted as the position of the US Food and Drug Administration.
- 5.Food and Drug Administration, HHS. 21 CFR 314.80: Post marketing reporting of adverse drug experiences 2017. https://www.gpo.gov/fdsys/pkg/CFR-2011-title21-vol5/pdf/CFR-2011-title21-vol5-sec314-80.pdf. Accessed 30 Jul 2017.
- 6.Bellis JR, Kirkham JJ, Thiesen S, Conroy EJ, Bracken LE, Mannix HL, et al. Adverse drug reactions and off-label and unlicensed medicines in children: a nested case-control study of inpatients in a pediatric hospital. BMC Med. 2013;7(11):238. https://doi.org/10.1186/1741-7015-11-238.CrossRefGoogle Scholar
- 7.Alamu JO. Evaluation of antimicrobial use in a pediatric intensive care unit. Ph.D. (Doctor of Philosophy) thesis, University of Iowa. 2009. http://ir.uiowa.edu/etd/277. Accessed 06 Jun 2017.
- 8.Tobias JD. Sedation in the intensive care unit: challenges, outcomes, and failure strategies. In: Manson KP, editor. Pediatric sedation outside of the operating room: a multispecialty international collaboration. New York: Springer; 2015. p. 125–49.Google Scholar
- 10.Zithromax (azithromycin) [package insert]. Pfizer, Inc. New York, NY; March 30, 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050670s032,050710s046,050711s043,050784s030lbl.pdf. Accessed 8 Jun 2017.
- 12.Fentanyl citrate [package insert]. Hospira Inc. Pfizer Inc. Lake Forest, IL; December 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019115s030s031lbl.pdf. Accessed 8 Jun 2017.
- 13.Prescilla RP. The pharmacology and clinical application of sedatives, analgesics, and adjuncts. In: Manson KP, editor. Pediatric sedation outside of the operating room: a multispecialty international collaboration. New York: Springer; 2015. p. 125–49.Google Scholar
- 15.Institute for Safe Medication Practices. QuarterWatch (special report, 2014): Adverse drug events in children less than 18 years old. 2017. https://www.ismp.org/newsletters/acutecare/showarticle.aspx?id=67. Accessed 01 Aug 2017.
- 18.U.S. Food and Drug Administration. CFR—Code of Federal Regulations Title 21. 2017. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=201.57. Accessed 30 Dec 2017.
- 19.Brunton LL, Knollmann BC, Hilal-Dandan R. Goodman and Gilman’s the pharmacological basis of therapeutics. 13th ed. New York: McGraw Hill Medical; 2018.Google Scholar
- 24.Institute for Safe Medication Practices List of High-Alert Medication. 2017. http://www.ismp.org/Tools/institutionalhighAlert.asp. Accessed 6 Jun 2017.
- 25.BPCA priority list of pediatric therapeutic needs. 2017. http://bpca.nichd.nih.gov/prioritization/status.cfm. Accessed 6 Jun 2017.